Back to top
more

Loncar Cancer Immunotherapy ETF: (CNCR)

(Real Time Quote from BATS) As of Apr 20, 2018 03:58 PM ET

 Add to portfolio

$26.59 USD

26.5889
19,107

-0.16 (-0.60%)

Volume: 19,107

Zacks ETF Rank 3 - Hold     3    

This is our ETF rating system that serves as a timeliness indicator for ETFs over the next 6 months:

Zacks Rank Definition
1 Strong Buy
2 Buy
3 Hold
4 Sell
5 Strong Sell

See all the Top Ranked ETFs here - The complete list of all the top ranked ETFs

ETF Quote Details

Previous Close 26.81
Open 26.75
Bid 26.25
Ask 29.56
Day Low-High 26.48-26.78
52wk Low-High 21.13-32.32
Volume 19,107
NAV (month end) NA

Zacks Premium Research for CNCR

Zacks ETF Rank Hold 3
ETF Risk High

Zacks proprietary quantitative models divide each set of ETFs following a similar investment strategy (style box/industry/asset class) into three risk categories- High, Medium, and Low. The aim of our models is to select the best ETFs within each risk category, so that investors can pick an ETF that matches their particular risk preference in order to better achieve their investment goals.

This is our ETF rating system that serves as a timeliness indicator for ETFs over the next 6 months:

Zacks Rank Definition
1 Strong Buy
2 Buy
3 Hold
4 Sell
5 Strong Sell

See all the Top Ranked ETFs here - The complete list of all the top ranked ETFs

ETF Expense Ratio

Expense Ratio 0.79%
Dividend (Yield) $0.35 (1.32%)
Issuer LONCAR INVESTMENTS

Benchmark for CNCR

LONCAR CANCER IMMUNOTHERAPY INDEX

The Loncar Cancer Immunotherapy Index seeks to track the combined performance of a basket of companies that develop therapies to treat cancer by harnessing the bodys own immune system.

Fund Summary for CNCR

LONCAR CANCER IMMUNOTHERAPY ETF

The Loncar Cancer Immunotherapy ETF seeks to track the Loncar Cancer Immunotherapy Index.